Unorthodox JAK Inhibitor Dosing in Pediatric Moderate-to-Severe Alopecia Areata: A Comparative Evaluation of Tofacitinib and Baricitinib

Patient Information

This report analyzes a cohort of one hundred pediatric patients diagnosed with moderate-to-severe alopecia areata (AA). The participants presented with significant scalp hair loss, quantified by the Severity of Alopecia Tool (SALT) score, ranging from 21 to 100. This demographic includes children and adolescents who frequently experience psychological distress due to the unpredictable nature of hair loss and the limited availability of FDA-approved treatments for the pediatric population. The clinical objective was to address extensive hair loss where topical therapies had typically failed.

Diagnosis

The primary diagnosis for all patients was Alopecia Areata, an autoimmune condition characterized by non-scarring hair loss. Diagnosis was confirmed through clinical examination and assessment of the SALT score. Patients were stratified into three severity categories based on their baseline hair loss: moderate (SALT score 21-49), severe (SALT score 50-94), and very severe (SALT score 95-100). The presence of ‘exclamation mark’ hairs and smooth, circumscribed patches supported the diagnosis.

Differential Diagnosis

In the evaluation of these pediatric patients, several conditions were considered and ruled out through clinical history and physical examination:
1. **Trichotillomania**: Ruled out by the lack of irregular, broken hairs of varying lengths and the absence of traction-related patterns.
2. **Tinea Capitis**: Excluded due to the absence of scaling, lymphadenopathy, and fungal elements on clinical inspection.
3. **Telogen Effluvium**: Ruled out as the hair loss was patchy and progressive rather than diffuse and sudden following a systemic stressor.
4. **Cicatricial (Scarring) Alopecia**: Ruled out by the preservation of follicular orifices.

Treatment and Management

The patients were enrolled in a randomized clinical study to evaluate the efficacy of Janus kinase (JAK) inhibitors using unorthodox dosing regimens. The 100 patients were randomized 1:1 into two groups:
– **Group A (n = 51)**: Received Tofacitinib.
– **Group B (n = 49)**: Received Baricitinib.

Unorthodox dosing refers to regimens tailored specifically for this study, differing from standard adult dosages. Management included regular monitoring for 24 weeks, focusing on both the regrowth of hair and the safety profile of these systemic medications in children. Supportive care involved periodic laboratory assessments to monitor for hematologic or metabolic changes commonly associated with JAK inhibitors.

Outcome and Prognosis

At the 24-week endpoint, both treatments showed significant hair regrowth with comparable efficacy.
– **Moderate Patients**: 33.33% of those on tofacitinib and 41.18% on baricitinib achieved a SALT score ≤10 (P = .87).
– **Severe Patients**: 45.45% of those on tofacitinib and 30.77% on baricitinib achieved a SALT score ≤20 (P = .75).
– **Very Severe Patients**: 47.37% of those on tofacitinib and 31.58% on baricitinib achieved a SALT score ≤20 (P = .51).

Secondary outcomes revealed that 36.73% of the baricitinib group achieved SALT90 (90% regrowth), which was numerically higher than the 21.57% in the tofacitinib group, though not statistically significant (P = .16). Both medications were well-tolerated; no serious adverse events occurred during the 24-week period. The prognosis for these patients is favorable for short-term regrowth, though long-term maintenance remains a subject of ongoing study.

Discussion

The use of JAK inhibitors like tofacitinib and baricitinib represents a significant shift in the management of pediatric alopecia areata, where treatment options were previously limited to corticosteroids or contact immunotherapy. This study is noteworthy for evaluating “unorthodox” dosing, which suggests that flexible or non-traditional regimens may still provide therapeutic benefit without compromising safety.

The findings indicate that while both drugs are effective, neither demonstrated a statistically significant superiority over the other in achieving primary endpoints. The lack of serious adverse events is particularly encouraging for the pediatric population, although the 24-week duration limits our understanding of long-term safety and the potential for relapse after discontinuation. These results support the consideration of JAK inhibitors as a viable short-term intervention for children with significant hair loss, particularly when conventional therapies are ineffective.

References

Wan M, Zhang M, Song X, et al. Tolerability and efficacy of unorthodox dosing regimens of tofacitinib and baricitinib in pediatric patients with moderate to severe alopecia areata. J Am Acad Dermatol. 2026 Mar;94(3):810-818. doi: 10.1016/j.jaad.2025.10.030.